17341293

Source:http://linkedlifedata.com/resource/pubmed/id/17341293

Download in:

Switch to

Custom View

Named Graph Language Inference

Statements in which the resource exists as a subject.
Predicate	Object
rdf:type	pubmed:Citation
lifeskim:mentions	umls-concept:C0007131, umls-concept:C0013216, umls-concept:C0030705, umls-concept:C0086960, umls-concept:C0178602, umls-concept:C0205179, umls-concept:C0282460, umls-concept:C1554217, umls-concept:C1701991
pubmed:dateCreated	2007-3-26
pubmed:abstractText	C.E.R.A. (Continuous Erythropoietin Receptor Activator) is an innovative agent with unique erythropoietin receptor activity and prolonged half-life. This study evaluated C.E.R.A. once weekly (QW) or once every 3 weeks (Q3W) in patients with anemia and advanced non-small cell lung cancer (NSCLC) receiving chemotherapy.
pubmed:commentsCorrections	http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-10408844, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-10511589, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-10541299, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-10638973, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-11387359, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-11432888, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-11745199, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-12011126, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-12074326, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-12189224, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-12208573, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-12209755, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-12468152, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-12504043, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-12671693, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-12877665, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-12877666, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-1373333, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-14596691, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-14662041, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-15015984, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-15364140, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-15474662, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-15561813, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-15661684, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-15812074, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-15911237, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-16177289, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-16191450, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-16232379, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-16485917, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-1651993, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-16570051, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-1752115, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-9166485, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-9671330, http://linkedlifedata.com/resource/pubmed/commentcorrection/17341293-9971869
pubmed:language	eng
pubmed:journal	http://linkedlifedata.com/resource/pubmed/journal/101263253
pubmed:status	PubMed-not-MEDLINE
pubmed:issn	1745-6215
pubmed:author	pubmed-author:EidJoseph EJE, pubmed-author:GlaspyJohnJ, pubmed-author:HirshVeraV, pubmed-author:MainwaringPaulP, pubmed-author:ManegoldChristianC, pubmed-author:RamlauRodrygR
pubmed:issnType	Electronic
pubmed:volume	8
pubmed:owner	NLM
pubmed:authorsComplete	Y
pubmed:pagination	8
pubmed:dateRevised	2009-11-18
pubmed:year	2007
pubmed:articleTitle	Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy.
pubmed:affiliation	Royal Victoria Hospital, McGill University Health Center, Montreal, Quebec, Canada. vera.hirsh@muhc.mcgill.ca
pubmed:publicationType	Journal Article